CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian ...
Phase 1
Westwood, Kansas, United States and 3 other locations
study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already ...
Phase 3
Kansas City, Kansas, United States and 82 other locations
as "study drug". The study is focused on patients who have advanced ovarian cancer.The aim of the study is to see how safe, tolerab...
Phase 2
Westwood, Kansas, United States and 23 other locations
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin A...
Phase 3
Kansas City, Kansas, United States and 50 other locations
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors...
Phase 1, Phase 2
Westwood, Kansas, United States and 37 other locations
following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...
Phase 3
Westwood, Kansas, United States and 237 other locations
as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high fola...
Phase 3
Westwood, Kansas, United States and 265 other locations
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall surviva...
Phase 3
Overland Park, Kansas, United States and 116 other locations
global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers...
Phase 2
Kansas City, Missouri, United States and 44 other locations
(PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors...
Phase 1
Kansas City, Missouri, United States and 15 other locations
Clinical trials
Research sites
Resources
Legal